Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody

Nature Structural and Molecular Biology

Volumn 13, Issue 8, 2006, Pages 740-747

  Luftig, Micah A ^a   Mattu, Marco ^a   Di Giovine, Paolo ^a   Geleziunas, Romas ^b,c   Hrin, Renee ^b   Barbato, Gaetano ^a   Bianchi, Elisabetta ^a   Miller, Michael D ^b   Pessi, Antonello ^a   Carfí, Andrea ^a  

^a IRBM   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLYCOPROTEIN; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D5; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN 5 HELIX; UNCLASSIFIED DRUG;

ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CRYSTAL STRUCTURE; H2 LOOP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYDROPHOBICITY; IMMUNOGLOBULIN STRUCTURE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; HYDROPHOBICITY; LEUCINE; MODELS, MOLECULAR; MUTATION; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; TRYPTOPHAN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33746810900     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb1127     Document Type: Article

References (50)

1. Burton, D.R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233-236 (2004).
2. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888 (1998).
3. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
4. Kwong, P.D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002).
5. Poignard, P., Saphire, E.O., Parren, P.W. & Burton, D.R. gp120: biologic aspects of structural features. Annu. Rev. Immunol. 19, 253-274 (2001).
6. Zwick, M.B., Saphire, E.O. & Burton, D.R. gp41: HIV's shy protein. Nat. Med. 10, 133-134 (2004).
7. Burton, D.R., Stanfield, R.L. & Wilson, I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 102, 14943-14948 (2005).
8. Calarese, D.A. et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071 (2003).
9. Saphire, E.O. et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 1155-1159 (2001).
10. Stanfield, R.L., Gorny, M.K., Williams, C., Zolla-Pazner, S. & Wilson, I.A. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 12, 193-204 (2004).
11. Thali, M. et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67, 3978-3988 (1993).
12. Labrijn, A.F. et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77, 10557-10565 (2003).
13. Conley, A.J. et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91, 3348-3352 (1994).
14. Zwick, M.B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892-10905 (2001).
15. Zwick, M.B. et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J. Virol. 78, 3155-3161 (2004).
16. Baba, T.W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206 (2000).
17. Mascola, J.R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210 (2000).
18. Veazey, R.S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346 (2003).
19. Mascola, J.R. et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009-4018 (1999).
20. Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615-622 (2005).
21. Tan, K., Liu, J., Wang, J., Shen, S. & Lu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 94, 12303-12308 (1997).
22. Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J. & Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430 (1997).
23. Chan, D.C., Fass, D., Berger, J.M. & Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997).
24. Furuta, R.A., Wild, C.T., Weng, Y. & Weiss, C.D. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5, 276-279 (1998).
25. Wild, C., Oas, T., McDanal, C., Bolognesi, D. & Matthews, T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA 89, 10537-10541 (1992).
26. Ferrer, M. et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. 6, 953-960 (1999).
27. Eckert, D.M., Malashkevich, V.N., Hong, L.H., Carr, P.A. & Kim, P.S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99, 103-115 (1999).
28. Lalezari, J.P. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 2175-2185 (2003).
29. Sanders, R.W., Korber, B., Lu, M., Berkhout, B. & Moore, J.P. Mutational analyses and natural variability of the gp41 ectodomain. in HIV Sequence Compendium (eds. Kuiken C. et al.) 43-68 (Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, USA, 2002).
30. Hamburger, A.E., Kim, S., Welch, B.D. & Kay, M.S. Steric accessibility of the HIV-1 gp41 N-trimer region. J. Biol. Chem. 280, 12567-12572 (2005).
31. Louis, J.M., Nesheiwat, I., Chang, L., Clore, G.M. & Bewley, C.A. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 278, 20278-20285 (2003).
32. Miller, M.D. et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. USA 102, 14759-14764 (2005).
33. Root, M.J., Kay, M.S. & Kim, P.S. Protein design of an HIV-1 entry inhibitor. Science 291, 884-888 (2001).
34. Eckert, D.M. & Kim, P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. USA 98, 11187-11192 (2001).
35. Al-Lazikani, B., Lesk, A.M. & Chothia, C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273, 927-948 (1997).
36. Sundberg, E.J. & Mariuzza, R.A. Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61, 119-160 (2002).
37. Lawrence, M.C. & Colman, P.M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946-950 (1993).
38. Davies, D.R. & Cohen, G.H. Interactions of protein antigens with antibodies. Proc. Natl. Acad. Sci. USA 93, 7-12 (1996).
39. Zhou, G. et al. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg. Med. Chem. 8, 2219-2227 (2000).
40. Huang, C.C. et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. USA 101, 2706-2711 (2004).
41. Yang, X., Kurteva, S., Lee, S. & Sodroski, J. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J. Virol. 79, 3500-3508 (2005).
42. Zhang, M.Y. et al. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J. Virol. 78, 9233-9242 (2004).
43. Munoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E. & Blumenthal, R. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. 140, 315-323 (1998).
44. Selzer, T., Albeck, S. & Schreiber, G. Rational design of faster associating and tighter binding protein complexes. Nat. Struct. Biol. 7, 537-541 (2000).
45. MacCallum, R.M., Martin, A.C. & Thornton, J.M. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol. 262, 732-745 (1996).
46. Lobo, E.D., Hansen, R.J. & Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93, 2645-2668 (2004).
47. Li, A. et al. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum. Retroviruses 13, 647-656 (1997).
48. Bianchi, E. et al. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. USA 102, 12903-12908 (2005).
49. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
50. Perrakis, A., Morris, R. & Lamzin, V.S. Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 6, 458-463 (1999).